ClinicalTrials.gg
CompletedNCT05624710Updated Aug 3, 2025

A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

A Phase 1 interventional study of INCB054707 in Renal Insufficiency and Kidney Diseases, sponsored by Incyte Corporation. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-03.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2023, 3 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
290th of 468
25 · median 32
Started
2022
with 25 others
Phase 1
232 of 553
14 open now
Registered
476th of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 290th largest by enrollment of the 468 interventional ones that give a count, is one of 26 that started in 2022, is one of 232 in phase 1, and was the 476th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, open-label, parallel-group study to evaluate INCB054707 in participants with varying levels of renal function or impairment.

03

Conditions studied

  • Renal Insufficiency
  • Kidney Diseases

Keywords

  • renal impairment
  • hemodialysis
  • Kidney failure
  • end-stage renal disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Participants with hepatic impairment will be classified at screening based on score. Classification will be repeated at check-in and should not be significantly different.

If the hepatic function classification for the participant is not similar at the 2 timepoints, enrollment of the participant into a hepatic category group will be at the discretion of the investigator, in consultation with the sponsor's medical monitor. The enrollment group will be based on the results at screening.

  • Participants eligible for Group 4 (normal hepatic function) should be in good health as determined by no findings in the medical history, physical examination, vital signs, 12-lead ECGs, or laboratory examinations at screening or check-in.
  • Participants eligible for Groups 1 through 3 may have medical findings consistent with their degree of hepatic dysfunction, as determined by medical history, physical examination, vital signs, 12-lead ECGs, and clinical laboratory examinations at screening and check-in. Participants with abnormal findings considered not clinically significant by the investigator are eligible.
  • within the range of 18.0 to 44.0 kg/m2 (inclusive) at screening.
  • Willingness to avoid pregnancy or fathering children.

Exclusion criteria

Exclusion Criteria:

  • the opinion of the principal investigator, history of uncontrolled or unstable cardiovascular, respiratory, renal, GI, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening or evidence of rapidly deteriorating hepatic function.
  • Serum corrected calcium and phosphorus levels over the upper limits of the institutional normal ranges.
  • History or current diagnosis of uncontrolled or significant cardiac disease indicating significant risk of safety for participation in the study, including any of the following:

    1. Recent myocardial infarction (within 6 months of check-in).
    2. Class III or IV congestive heart failure.
    3. Unstable angina (within 6 months of check-in).
    4. (symptomatic) cardiac arrhythmias (eg, sustained ventricular tachycardia, second or third degree atrioventricular block without a pacemaker).
    5. Uncontrolled hypertension.
  • A current, functioning organ transplant or a scheduled organ transplant in the next 6 weeks from check-in.
  • History of within 5 years of screening, with the exception of cured basal cell carcinoma, squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer.
  • History of clinically significant GI disease or surgery (cholecystectomy and appendectomy are allowed) that could impact the absorption of study drug.
  • Severe ascites (ascites requiring paracentesis more than every 4 weeks) or an encephalopathy ≥ Grade 2 (precludes them from understanding and signing an ).
  • Any major surgery within 4 weeks of screening.
  • Donation of blood to a blood bank within 4 weeks of screening (within 2 weeks for plasma only).
  • Blood transfusion within 4 weeks of check-in.
  • Current or recent history (within 30 days before screening) of a clinically significant bacterial, fungal, parasitic, or mycobacterial infection, or currently receiving systemic antibiotics or current clinically significant viral infection at screening or check-in.
  • Positive serology for (eg, HBsAg) or . Participants whose results are compatible with immunity due to infection or prior immunization for HBV may be included at the discretion of the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Group 1: Severe Hepatic Impairment

    Participants with severe hepatic impairment (Class C Child-Pugh score) will receive a single oral dose of INCB054707 on Day 1.

    Drug: INCB054707

  • Experimental
    Group 2: Moderate Hepatic Impairment

    Participants with moderate hepatic impairment (Class B Child-Pugh score) will receive a single oral dose of INCB054707 on Day 1.

    Drug: INCB054707

  • Experimental
    Group 3: Mild Hepatic Impairment

    Participants with mild hepatic impairment (Class A Child-Pugh score) will receive a single oral dose of INCB054707 on Day 1.

    Drug: INCB054707

  • Experimental
    Group D: Normal Hepatic Function

    Participants with normal hepatic function will receive a single oral dose of INCB054707 on Day 1.

    Drug: INCB054707

Interventions

  • INCB054707 75 mg will be administered orally on Day 1.

    Also known as: Povorcitinib

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics Parameter: Cmax of INCBC054707

    Defined as maximum observed plasma concentration of INCB054707

    Time frame: Days 1 - 5

  2. Pharmacokinetics Parameter: AUC(0-t) of INCB054707

    Defined as the area under the concentration- time curve up to the last measurable concentration of INCB54707.

    Time frame: Days 1 - 5

  3. Pharmacokinetics Parameter: AUC(0-∞) of INCB054707

    Defined as area under the concentration-time curve From 0 to Infinity of INCB054707

    Time frame: Days 1 - 5

Secondary outcomes

  1. Number of Treatment Emergent Adverse Events (TEAE'S)

    Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.

    Time frame: up to 15 days

  2. Pharmacokinetics Parameter: tmax of INCB054707

    Defined as time to reach maximum plasma concentration of INCB054707

    Time frame: Days 1 - 5

  3. Pharmacokinetics Parameter: t1/2 0f INCB054707

    Defined as apparent terminal phase disposition half-life of INCB54707

    Time frame: Days 1 - 5

  4. Pharmacokinetics Parameter: CL/F of INCB054707

    Defined as oral dose clearance of INCB054707

    Time frame: Days 1 - 5

  5. Pharmacokinetics Parameter:: Vz/F of INCB054707

    Defined as apparent oral dose volume of distribution of INCB054707

    Time frame: Days 1 - 5

07

Study locations

4 sites
  • Orange County Research Center
    Tustin, California 92780, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Texas Liver Institute Tli the Liver Institute of South Texas List Downtown Office
    San Antonio, Texas 78215, United States
  • Apex Gmbh
    Munich, D-81241, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Jun 2023, 6 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 6 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2022
First posted
Nov 22, 2022
StartActual
Dec 8, 2022
Primary completionActual
Jun 30, 2023
CompletionActual
Jun 30, 2023
Last update
Aug 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05624710
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Nov 22, 2022
Start date
Dec 8, 2022
Primary completion
Jun 30, 2023
Completion
Jun 30, 2023
Last update
Aug 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povorcitinib

Start the discussion